Physician profile
Steven M Morrison
NPI 1821002296
$2,458.71
in general payments reported to CMS, 2019-2025
29 companies · $13.57 in 2025
The $13.57 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $349 · 2020: $119 · 2021: $439 · 2022: $353 · 2023: $342 · 2024: $844 · 2025: $13.57.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,199.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $693.09 | 2021-2024 | Qelbree |
| Glaxosmithkline, LLC. | $380.85 | 2019-2024 | Bexsero, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $323.54 | 2019-2024 | Jardiance |
| Abbvie INC. | $163.96 | 2021-2024 | |
| Genentech USA, INC. | $104.82 | 2019-2022 | |
| Novo Nordisk INC | $85.19 | 2019-2024 | Ozempic, Rybelsus |
| Pfizer INC. | $75.70 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $72.36 | 2020-2023 | Vaxneuvance, M-M-R II, Proquad |
| Takeda Pharmaceuticals U.S.A., INC. | $62.08 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $50.99 | 2022 | |
| Astellas Pharma US INC | $43.89 | 2019 | |
| Abbott Laboratories | $39.84 | 2021 | |
| Sanofi Pasteur INC. | $37.79 | 2019-2022 | |
| Medtronic, INC. | $31.58 | 2023 | Venaseal |
| Kaleo, INC. | $29.47 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $29.15 | 2019 | |
| Cranial Technologies, INC | $27.96 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $26.91 | 2021 | |
| Inspire Medical Systems, INC. | $24.62 | 2024 | Inspire |
| Amgen INC. | $24.31 | 2019 | |
| Tris Pharma INC | $22.61 | 2020 | |
| Dynavax Technologies Corporation | $16.41 | 2022 | |
| Dexcom, INC. | $15.48 | 2023 | Dexcom G6 Transmitter |
| Allergan, INC. | $14.68 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.57 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $13.57 | 2025 | Zoryve |
| Teva Pharmaceuticals USA, INC. | $12.12 | 2019 | |
| Lilly USA, LLC | $11.11 | 2020 | |
| Vistapharm, INC. | $11.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Morrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.